Using 3D technology to improve diagnosis and treatment of primary liver cancer

A Multicenter Randomized Controlled Clinical Study of 3d Visualization Technology in the Diagnosis and Treatment of Primary Liver Cancer

This study tests if using 3D imaging technology during surgery can help people with primary liver cancer have better outcomes compared to standard imaging methods.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 420 (estimated)
• Ages: 18 Years to 66 Years
• Sex: All
• Sponsor: Zhujiang Hospital (other)
• Locations: 1 site (Guangzhou, Guangdong)
• Trial ID: NCT05118451 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of three-dimensional (3D) visualization technology in the diagnosis and treatment of primary liver cancer. Patients will undergo surgical treatment guided by high-quality thin-slice CT images reconstructed into 3D models, which aim to enhance surgical planning and navigation. The study compares outcomes between patients receiving 3D-guided surgery and those receiving standard CT-guided surgery. The goal is to reduce recurrence rates and improve surgical success through better preoperative planning and intraoperative guidance.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18-66 with clinically diagnosed primary liver cancer, tumors between 3cm and 10cm, and Child-Pugh liver function grades A or B.

Not a fit: Patients with severe comorbidities that prevent surgery or those with advanced liver dysfunction (Child-Pugh grade C) may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly reduce recurrence rates and improve surgical outcomes for patients with primary liver cancer.

How similar studies have performed: Previous studies have shown promising results using advanced imaging technologies in surgical planning, suggesting potential success for this novel approach.

Eligibility criteria

Inclusion Criteria:

* Patients with primary liver cancer clinically diagnosed preoperatively (tumor ≥3cm to ≤10cm, diagnostic criteria: Primary liver cancer Diagnosis and Treatment Code 2019 edition);
* No tumor thrombi formation and distant metastasis were found in the imaging data;
* Child-Pugh grading standard of liver function was GRADE A or B;
* 18-66 years old;
* Complete clinical case data;
* all patients underwent surgical treatment;
* Voluntarily participate in the study and sign the informed consent.

Exclusion Criteria:

* There are basic diseases that cannot tolerate surgery (such as severe cardiopulmonary cerebral renal insufficiency);
* Preoperative imaging examination found cancer thrombus in main portal vein and branches, common hepatic vein and branches, main hepatic vein and branches and inferior vena cava;
* planned pregnancy, unplanned pregnancy and pregnancy;
* Preoperative child-Pugh grading standard of liver function was Grade C.
* Disease researchers that the investigator considers inappropriate to participate in this clinical trial.

Where this trial is running

Guangzhou, Guangdong

• MI-3DVS — Guangzhou, Guangdong, China (RECRUITING)

Study contacts

• Study coordinator: Chihua Fang, MD

Conditions: Primary Liver Cancers, primary liver cancer, RCT, recurrence, 3D